NewzA child has died during a gene editing clinical trial conducted by a Chinese startup, marking a recurring issue in the country's biotechnology sector. The incident has prompted renewed international scrutiny regarding the transparency and safety protocols governing experimental gene therapies in China.
The event follows a high-profile presentation given by HuidaGene CEO Alvin Luk at the American Society for Gene and Cell Therapy annual convention in New Orleans last year. During that symposium, the company showcased data from its research, which is now being re-examined in light of the reported fatality.
In-depth summary · AI, neutral